BioFuels Journal

Cambridge MA—Verenium Corporation (Nasdaq: VRNM), a pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, reported March 11 financial results for the fourth quarter and year ended December 31, 2009.

The Company also provided a summary of recent highlights and accomplishments.

Full Verenium Report

Comments

"I am pleased to report that although 2009 was a challenging year both from an economic and industry perspective, Verenium remained focused on its overall goals and continued to execute against key corporate initiatives," said Carlos A. Riva, President and Chief Executive Officer of Verenium.

"Verenium made significant progress throughout 2009 creating a stronger business platform and better positioning it for future commercial success."

"The growth we achieved in our product gross margin dollars in 2009 demonstrates the underlying strength of our enzyme business," said James E. Levine, Executive Vice President and Chief Financial Officer.

"We look forward to further progress in 2010."

Total revenues for the fourth quarter and year ended December 31, 2009 were $16.6 million and $65.9 million, respectively, compared to $19.7 million and $69.7 million for the same periods in the prior year, with product revenues representing more than 60 percent of total revenues in all periods.

Product revenues for the fourth quarter and year ended December 31, 2009 were $11.9 million and $44.0 million, respectively, compared to $12.1 million and $49.1 million for same periods in the prior year, representing a 2 percent decrease for the fourth quarter and 10 percent decrease for the year ended December 31, 2009, primarily reflecting the impact of a shift in a portion of manufacturing volume of Phyzyme from the Company's toll manufacturing facility in Mexico City to Genencor's manufacturing facility.

Pursuant to current accounting rules, for sales of Phyzyme manufactured by Genencor, an affiliate of Danisco, the Company recognizes revenue only for the amount of the royalty from Danisco, whereas for product supplied through the toll manufacturing facility in Mexico City, the Company recognizes revenue for the sale of the product to Danisco at cost, along with the royalty revenue.

The decrease in product revenue for the year ended December 31, 2009 also reflects the Company's discontinuation of its Bayovac-SRS and Quantum product lines during early 2008.

The decrease in these product revenues was offset in part by an increase in revenues from the Company's Fuelzyme, Veretase and Xylathin enzymes.

Product gross margin dollars increased in the fourth quarter and for the full year ended December 31, 2009, versus the same periods in the prior year, due primarily to an increase in Phyzyme royalties from Danisco, a shift in product mix to higher margin products and a reduction in inventory losses compared to 2008 related to contamination issues in the Phyzyme enzyme manufacturing process, which resulted in a lower product gross margin dollars in 2008.

Excluding cost of product revenues, total operating expenses decreased to $20.4 million and $102.3 million for the fourth quarter and year ended December 31, 2009 from $30.7 million and $214.4 million for the fourth quarter and year ended December 31, 2008.

The year-over-year decrease in total gross operating expenses (excluding cost of product revenues) relates primarily to the $106.1 million non-cash goodwill impairment charge recorded in September 2008.

Excluding the goodwill impairment charge, total operating expenses (excluding cost of product revenues) decreased $5.9 million for the year ended December 31, 2009 as compared to the same period in 2008, primarily due to aggressive expense management.

Total operating expenses include gross expenses incurred to support ongoing development related to the Company's consolidated joint ventures with BP, Galaxy and Vercipia.

BP's share of the total operating expenses of the joint ventures was $8.8 million and $34.3 million for the fourth quarter and year ended December 31, 2009 and $7.5 million and $12.5 million for the fourth quarter and year ended December 31, 2008, and is included below operating expenses as "Loss attributed to non-controlling interest in consolidated entities" on the Company's Consolidated Income Statement.

On a non-GAAP basis, net of BP's share of expenses, pro forma net operating expenses decreased as compared to prior periods, reflecting the cost sharing and the Company's expense minimization efforts.

Interest expense related almost exclusively to the cash and non-cash interest expense from the Company's convertible debt instruments.

Of total net interest expense for the fourth quarter and year ended December 31, 2009, $0.5 million and $4.0 million, respectively, represents non-cash interest expense related to the Company's convertible notes, compared to $1.6 million and $5.4 million in non-cash interest for the same periods in 2008.

Net loss attributed to Verenium for the quarter and year ended December 31, 2009 was $3.0 million and $21.9 million, respectively, compared to $11.9 million and $176.5 million for the same periods in 2008.

Adjusted for the non-cash impact of accounting related to the 8% and 9% convertible notes and non-cash goodwill impairment charge, the Company's non-GAAP pro-forma net loss for the quarter and year ended December 31, 2009 was $3.5 million and $40.1 million, as compared to $14.1 million and $70.1 million for the same periods in the prior year.

The Company believes that excluding the non-cash impact of these items provides a more consistent measure of operating results.

As of December 31, 2009, the Company had unrestricted cash and cash equivalents totaling approximately $32.1 million, of which $7.2 million was held by the Company's consolidated joint venture with BP, Vercipia, which is available solely for the operations of Vercipia.

For more information, call 617-674-5335.

See Related Websites/Articles:

• Verenium Corp.
• Full Verenium Report

more ADVANCED BIOFUELS...